Essential Tremor News and Research

RSS

St. Jude Medical's Epiducer lead delivery system for neurostimulation therapy receives CE Mark approval

St. Jude Medical, Inc., a global medical device company, today announced European CE Mark approval of its new Epiducer™ lead delivery system for neurostimulation therapy. Unveiled at the Neurosurgery 2010 Congress in Lyon, France, the Epiducer lead delivery system is the first of its kind, allowing introduction of S-Series perc-paddle leads as well as multiple lead arrays through a single percutaneous entry point.

27 May 2010

St. Jude Medical's Brio DBS system for treating Parkinson’s disease receives Australian TGA approval

St. Jude Medical, Inc., a global medical device company, today announced regulatory and reimbursement approval from the Australian Therapeutic Goods Administration of its Brio™ deep brain stimulation system for treating the symptoms of Parkinson’s disease.

23 Mar 2010

Manhattan Pharmaceuticals to merge with Ariston Pharmaceuticals

Manhattan Pharmaceuticals, Inc. today announced it has entered into a definitive agreement and plan of merger and completed the merger transaction with Ariston Pharmaceuticals, Inc., a privately-held, specialty pharmaceutical company. As a result of the merger, Ariston became a wholly owned subsidiary of Manhattan Pharmaceuticals.

12 Mar 2010

Study shows encouraging results of DBS in psychiatric disorder treatment

Psychosurgery is making a comeback. Recently published case series have shown encouraging results of so-called deep brain stimulation (DBS) in treatment-resistant obsessive-compulsive disorder, depressive disorders, and Tourette syndrome.

5 Mar 2010

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Scientists are beginning to find out why people with Parkinson's disease often feel socially awkward. Parkinson's patients find it harder to recognize expressions of emotion in other people's faces and voices, report two studies published by the American Psychological Association.

4 Mar 2010

Neurosurgical journals influence neurosurgeons and their patients

A compendium of articles in the Journal of Neurosurgery (JNS) provides evidence that specialty medical journals are not only an invaluable resource to physicians and researchers, but to the media and public. Clinical and basic science papers do not have to be published in large, high-impact publications to garner attention, and in fact when it comes to specialized areas of medicine such as neurosurgery, publications devoted to the subspecialty produce many citation classics. "Citation classic" is a term given to articles that have been cited more than 400 times.

18 Jan 2010

Taro Pharmaceutical Industries initiates its T2007 non-sedating barbiturate compound Phase I clinical trials

Taro Pharmaceutical Industries Ltd. announced that it has begun Phase I clinical trials in Canada with T2007, the second in the Company’s class of proprietary non-sedating barbiturate compounds to be approved for studies in humans.

18 Dec 2009

Taro Pharmaceutical Industries' non-sedating barbiturate compound study granted FDA IND exemption

Taro Pharmaceutical Industries Ltd. announced that it has been granted an Investigational New Drug (“IND”) exemption by the United States Food and Drug Administration, (“FDA”), to permit clinical studies on T2000 (1,3-dimethoxymethyl-5,5-diphenyl-barbituric acid), one of a class of non-sedating barbiturate compounds currently in development by the Company.

5 Dec 2009

Multidisciplinary pediatric neurosurgery program launched

Responding to a growing need in central and northeast Pennsylvania for highly specialized care of pediatric brain tumors and other central nervous system disorders, Geisinger's Janet Weis Children's Hospital has launched a state-of-the-art and comprehensive pediatric neurosurgery program. The multidisciplinary program is led by pediatric neurosurgeon Amir Kershenovich, M.D., who says he is pleased to accept his challenging role.

24 Nov 2009

Stereotactic radiosurgery effective in eliminating Parkinson's disease tremors

Stereotactic radiosurgery (SRS) offers a less invasive way to eliminate tremors caused by Parkinson's disease and essential tremor than deep brain stimulation (DBS) and radiofrequency (RF) treatments, and is as effective, according to a long-term study presented November 2, 2009, at the 51st Annual Meeting of the American Society for Radiation Oncology (ASTRO).

3 Nov 2009

Highlights of new cancer research to be presented at 51st ASTRO Annual Meeting

The following are highlights of new cancer research being presented at the American Society for Radiation Oncology's (ASTRO) 51st Annual Meeting on November 1-5, 2009, in Chicago.

29 Oct 2009

Deep brain stimulation: New treatment option for people with severe Tourette syndrome

Deep brain stimulation may be a safe and effective treatment for Tourette syndrome, according to research published in the October 27, 2009, print issue of Neurology®, the medical journal of the American Academy of Neurology.

27 Oct 2009

LINGO1 variant responsible for essential tremors and Parkinson's disease

Researchers at the Mayo Clinic campus in Florida and their collaborators worldwide have discovered that a single gene promotes development of essential tremor in some patients and Parkinson's disease in others.

2 Sep 2009

Study reveals that increased neurostimulation market offers growth for device industries

The device industry would do well to focus on the treatment needs of individuals suffering from nerve-related disorders as implanted technologies that deliver electrical stimulation begin to supplant drugs for treating certain nerve-related disorders.

24 Aug 2009

Transcranial MR-guided focused ultrasound for brain disorders a step closer

A team of researchers working at the MR-Center of the University Children's Hospital in Zürich has completed a pilot study using transcranial MR-guided focused ultrasound to treat 10 patients with neuropathic pain.

9 Aug 2009

St. Jude Medical announces first European patient implants of Libra deep brain stimulation systems for Parkinson’s Disease

St. Jude Medical, Inc. has announced the first patient implants of its Libra deep brain stimulation (DBS) system for treating the symptoms of Parkinson's disease, a progressive neurological disorder that affects a person's control over his or her movements and speech.

29 Mar 2009

University of Florida doctors test targets for Parkinson surgery

Doctors may be able to tailor a specialized form of brain surgery to more closely match the needs of Parkinson patients, according to results from the first large-scale effort to compare the two current target areas of deep brain stimulation surgery, or DBS.

15 Mar 2009

New guidelines say botulinum toxin effective for many neurological disorders, but not headache

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating a variety of neurological conditions. Surprisingly, the drug may not be effective for chronic headaches, accrding to Allison Brashear, M.D., professor and chairman of the Department of Neurology at Wake Forest University Baptist Medical Center, who helped develop the guidelines.

9 May 2008

Botulinum toxin is safe and effective for treating cervical dystonia

New guidelines developed by the American Academy of Neurology confirm that the drug botulinum toxin is safe and effective for treating cervical dystonia, a condition of involuntary head tilt or neck movement, spasticity and other forms of muscle overactivity that interfere with movement in adults and children with an upper motor neuron syndrome, and excessive sweating of the armpits and hands.

5 May 2008

Deep brain stimulation may help people with treatment resistant major depression

Researchers from the Cleveland Clinic, Brown University, and Massachusetts General Hospital will present results of a long-term outcome study that builds on previous promising research, which has shown that deep brain stimulation (DBS) is a potentially effective treatment option for people with treatment resistant major depression.

29 Apr 2008